

Ustekinumab in BEhçet's Syndrome Study

NCT07244614

Status	RECRUITING
Sponsor	Groupe français d'étude des Maladies Inflammatoires de l'oeil
Enrollment	208 participants

Key Eligibility Criteria

Inclusion (8)

- Age e 18 years old;
 - Non-opposition to study;
 - Use of contraceptive measures;
 - Fulfillment of the international classification criteria for Behçet's disease, revised in 2013;
 - Indication for ustekinumab or apremilast within the standard of care of mucocutaneous Behçet's syndrome
- ... and 3 more (see full listing online)

Exclusion (9)

- Pregnancy;
 - Previous treatment failure to ustekinumab;
 - Contraindications to ustekinumab, such as:
 - Active chronic infections (e.g., active tuberculosis, replicative hepatitis B, HIV, etc.) or malignancies;
 - Live vaccins in the past 3 months;
- ... and 4 more (see full listing online)

Locations (11 total)

CHU BORDEAUX Hôpital Saint-André - Service de médecine interne, Bordeaux, France
Service de médecine interne-APHP - Henri Mondor, Créteil, France
HOPITAL CROIX-ROUSSE - HCL - service de médecine interne, Lyon, France
... and 8 more locations